Back آسترازينيكا Arabic استرازينيكا ARZ آسترازنکا AZB AstraZeneca BCL AstraZeneca Catalan AstraZeneca Czech AstraZeneca Danish AstraZeneca German AstraZeneca Greek AstraZeneca EO
 | |
 AstraZeneca Central Cambridge Campus | |
| Company type | Public |
|---|---|
| |
| ISIN | GB0009895292 |
| Industry | |
| Predecessors | |
| Founded | 6 April 1999 |
| Headquarters | Cambridge Biomedical Campus, , England |
Area served | Global |
Key people |
|
| Products | |
| Revenue |  US$45.811 billion (2023)[1] |
| US$8.193 billion (2023)[1] | |
| US$5.961 billion (2023)[1] | |
| Total assets | US$101.119 billion (2023)[1] |
| Total equity | US$39.166 billion (2023)[1] |
Number of employees | 89,900 (2023)[1] |
| Subsidiaries | |
| Website | astrazeneca |
AstraZeneca plc (/ˌæstrəˈzɛnəkə/) (AZ) is a British-Swedish[2][3][4] multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom.[5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group[6][7] (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). It has its research and development concentrated in three strategic centres: Cambridge, United Kingdom; Gothenburg, Sweden[8][9] and Gaithersburg in Maryland, U.S.[10]
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Its British counterpart, Zeneca PLC was formed in 1993 when ICI divested its pharmaceuticals businesses; Astra AB and Zeneca PLC merged six years later, with the chosen headquarters in the United Kingdom.[11]
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide.[12]
- ^ a b c d e f "Annual Results 2023" (PDF). AstraZeneca. Retrieved 21 February 2024.
- ^ "AstraZeneca > GC Powerlist: Sweden Teams 2019". www.legal500.com. Retrieved 30 December 2020.
- ^ Hollingsworth, Julia; Renton, Adam; Macaya, Melissa; Hayes, Mike (30 December 2020). "UK "will be able to get out of this by the spring", minister says after regulator approves AstraZeneca vaccine". CNN. Retrieved 30 December 2020.
- ^ Arthur, Rachel (30 December 2020). "AstraZeneca's COVID-19 vaccine gets the green light in the UK". biopharma-reporter.com. Retrieved 30 December 2020.
- ^ "Registered office and corporate headquarters". AstraZeneca. Retrieved 27 February 2020.
- ^ "Global 500 – Pharmaceuticals". Fortune. 20 July 2009. Archived from the original on 23 August 2010. Retrieved 19 August 2010.
- ^ "Key facts". AstraZeneca. Archived from the original on 8 September 2010. Retrieved 1 September 2010.
- ^ "Gothenburg - AstraZeneca". www.astrazeneca.com. Retrieved 5 December 2024.
- ^ "AstraZenceca | Move to Gothenburg". www.movetogothenburg.com. Retrieved 5 December 2024.
- ^ Cite error: The named reference
Fierce2013reorgwas invoked but never defined (see the help page). - ^ "A history of AstraZeneca". pharmaphorum. 18 September 2020. Retrieved 29 October 2023.
- ^ "Largest pharma companies by market cap". companiesmarketcap.com. Retrieved 29 October 2023.